Tango Therapeutics Inc. (TNGX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Tango Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 26 | $221.08 | $722.15 | $501.07 | 226.65% |
 Farallon Capital Farallon Capital Management LLC | 9.1M | $58.08M | $254.5M | $196.42M | 338.18% |
| BG Bart Gancher Intech Investment Management LLC | 37,959 | $213,096.56 | $1.05M | $832,294.3 | 390.57% |
 Point72 Asset Management LP Point72 Asset Management LP | 533,937 | $4.49M | $14.7M | $10.22M | 227.86% |
 David Kim Paradigm Biocapital Advisors LP | 4.01M | $83.88M | $111.45M | $27.57M | 32.86% |
Tango Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John Newman Canaccord Genuity | 357.53 | $9,020.26 | $9,520.92 | $500.66 | 5.55% |
 Robert Driscoll Wedbush | 413.92 | $9,111.44 | $12,011.86 | $2,900.42 | 31.83% |
Tango Therapeutics Inc. (TNGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tango Therapeutics Inc. ever had a stock split?
Tango Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Malte Peters CEO | NASDAQ (NMS) Exchange | 87583X109 CUSIP |
| US Country | 137 Employees | - Last Dividend | - Last Split | 3 Sep 2020 IPO Date |
Overview
Tango Therapeutics, Inc. is a pioneering biotechnology firm engaged in the discovery and development of novel cancer treatments. With its foundation laid in 2017 and headquartered in Cambridge, Massachusetts, Tango's mission revolves around crafting innovative therapeutic strategies to tackle various cancer types. The company's robust research and development activities are highlighted by its strategic collaboration with Gilead Sciences, Inc., focusing on the discovery, development, and commercialization of a new pipeline of cancer therapies. This partnership underscores Tango Therapeutics' commitment to advancing the landscape of cancer treatment through cutting-edge scientific innovation and collaboration.
Products and Services
- TNG908
- Ubiquitin-specific protease 1 (USP1) inhibitor
- Target 3 inhibitor for STK11-mutant cancers
The flagship program of Tango Therapeutics, TNG908, stands as a testament to the company's innovative approach in cancer therapy. It is a synthetic lethal small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5). This drug candidate is primarily developed for treating cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. By inhibiting PRMT5, TNG908 disrupts the cancer cell's abnormal growth mechanisms, offering a novel approach to cancer treatment.
This therapeutic candidate marks another stride in Tango's commitment to addressing genetically defined cancers. The USP1 inhibitor is designed to treat patients harboring BRCA1 or BRCA2 mutations. These genetic alterations are commonly associated with a higher risk of developing several cancer types, including breast and ovarian cancer. By targeting USP1, Tango aims to exploit a critical vulnerability in cancer cells with these mutations, showcasing the potential for precision medicine in cancer care.
Further expanding its portfolio, Tango is developing a therapeutic product aimed at combating STK11-mutant cancers. Although specific details about this program are not disclosed, the focus on STK11 mutations—which are prevalent in certain lung cancers—illustrates Tango's commitment to targeting genetic drivers of cancer progression. This approach not only highlights the company's innovative edge but also its dedication to addressing unmet medical needs across various cancer patient populations.
